Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia

American Journal of Cardiology

Volumn 109, Issue 3, 2012, Pages 364-369

  Kawashiri, Masa Aki ^a,b   Nohara, Atsushi ^a   Noguchi, Tohru ^a   Tada, Hayato ^a   Nakanishi, Chiaki ^a   Mori, Mika ^a   Konno, Tetsuo ^a   Hayashi, Kenshi ^a   Fujino, Noboru ^a   Inazu, Akihiro ^a   Kobayashi, Junji ^a   Mabuchi, Hiroshi ^a   Yamagishi, Masakazu ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KKR Hokuriku Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTILAN; EZETIMIBE; KEXIN; KEXIN TYPE 9; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; ROSUVASTATIN; SUBTILISIN; UBIDECARENONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; HUMAN; MALE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANION EXCHANGE RESINS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPICHLOROHYDRIN; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; IMIDAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; RESINS, SYNTHETIC; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84855954546     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2011.09.019     Document Type: Article

References (21)

1. D.J. Rader, J. Cohen, H.H. Hobbs Monogenic hypercholesterolemia: new insights in pathogenesis and treatment J Clin Invest 111 2003 1795 1803 (Pubitemid 38057721)
2. M.A. Kawashiri, T. Higashikata, A. Nohara, J. Kobayashi, A. Inazu, J. Koizumi, H. Mabuchi Efficacy of colestimide coadministered with atorvastatin in Japanese patients with heterozygous familial hypercholesterolemia (FH) Circ J 69 2005 515 520 (Pubitemid 40745722)
3. M.H. Davidson, T. McGarry, R. Bettis, L. Melani, L.J. Lipka, A.P. LeBeaut, R. Suresh, S. Sun, E.P. Veltri Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia J Am Coll Cardiol 40 2002 2125 2134 (Pubitemid 36005898)
4. H. Mabuchi, T. Higashikata, M. Kawashiri, S. Katsuda, M. Mizuno, A. Nohara, A. Inazu, J. Koizumi, J. Kobayashi Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients J Atheroscler Thromb 12 2005 111 119
5. G. Welder, I. Zineh, M.A. Pacanowski, J.S. Troutt, G. Cao, R.J. Konrad High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol J Lipid Res 51 2010 2714 2721
6. H. Mabuchi, T. Higashikata, A. Nohara, H. Lu, W.X. Yu, T. Nozue, Y. Noji, S. Katsuda, M.A. Kawashiri, A. Inazu, J. Kobayashi, J. Koizumi Cutoff point separating affected and unaffected familial hypercholesterolemic patients validated by LDL-receptor gene mutants J Atheroscler Thromb 12 2005 35 40
7. W.T. Friedewald, R.I. Levy, D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
8. M.A. Kawashiri, A. Nohara, H. Tada, M. Mori, M. Tsuchida, S. Katsuda, A. Inazu, J. Kobayashi, J. Koizumi, H. Mabuchi, M. Yamagishi Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study Clin Pharmacol Ther 83 2008 731 739 (Pubitemid 351556020)
9. T. Noguchi, J. Kobayashi, K. Yagi, A. Nohara, N. Yamaaki, M. Sugihara, N. Ito, R. Oka, M.A. Kawashiri, H. Tada, M. Takata, A. Inazu, M. Yamagishi, H. Mabuchi Comparison of effects of Bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study Atherosclerosis 217 2011 165 170
10. T. Teramoto, J. Sasaki, H. Ueshima, G. Egusa, M. Kinoshita, K. Shimamoto, H. Daida, S. Biro, K. Hirobe, T. Funahashi, K. Yokote, M. Yokode Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese J Atheroscler Thromb 14 2007 45 50
11. National Cholesterol Education Program Expert on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
12. J.H. O'Keefe Jr, L. Cordain, W.H. Harris, R.M. Moe, R. Vogel Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal J Am Coll Cardiol 43 2004 2142 2146 (Pubitemid 38686815)
13. M. Tsuchida, M.A. Kawashiri, H. Tada, M. Takata, A. Nohara, H. Ino, A. Inazu, J. Kobayashi, J. Koizumi, H. Mabuchi, M. Yamagishi Marked aortic valve stenosis progression after receiving long-term aggressive cholesterol-lowering therapy using low-density lipoprotein apheresis in a patient with familial hypercholesterolemia Circ J 73 2009 963 966
14. H. Mabuchi, T. Higashikata, M.A. Kawashiri Clinical applications of long-term LDL-apheresis on and beyond refractory hypercholesterolemia Transfus Apher Sci 30 2004 233 243 (Pubitemid 38698338)
15. K.M. Dale, C.I. Coleman, N.N. Henyan, J. Kluger, C.M. White Statins and cancer risk: a meta-analysis JAMA 295 2006 74 80 (Pubitemid 43042692)
16. J.R. Kizer, C. Madias, B. Wilner, C.J. Vaughan, A.I. Mushlin, P. Trushin, A.M. Gotto Jr, R.C. Pasternak Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy Am J Cardiol 105 2010 1289 1296
17. J.M. McKenney Optimizing LDL-C lowering with statins Am J Ther 11 2004 54 59
18. A.J. Tremblay, B. Lamarche, V. Lemelin, L. Hoos, S. Benjannet, N.G. Seidah, H.R. Davis Jr, P. Couture Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men J Lipid Res 52 2011 558 565
19. M. Andrikoula, I.F. McDowell The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment Diabetes Obes Metab 10 2008 271 278 (Pubitemid 351386024)
20. The Lipid Research Clinics Coronary Primary Prevention Trial results I. Reduction in incidence of coronary heart disease JAMA 251 1984 351 364
21. G. Cao, Y.W. Qian, M.C. Kowala, R.J. Konrad Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease Endocrinol Metab Immune Disord Drug Targets 8 2008 238 243